Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 62

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 62
---
 Investor
and its counsel on the form and substance of, and shall give due consideration to all such comments from the Investor or its counsel on,
any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the Investor, its purchases hereunder
or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby (other than any press release, SEC
filing or other public disclosure that contains disclosures substantially similar to disclosures previously reviewed by the Investor or
its counsel), not less than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a
final version of any portion of such press release, SEC filing or other public disclosure relating to the Investor, its purchases hereunder
or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby at least 24 hours prior to any release,
issuance, filing or use by the Company thereof.

(j) . Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes
of this Agreement and the consummation of the transactions contemplated hereby.

(k) .

(l) . The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party. In addition, each and every reference to share prices
and Depositary Shares in this Agreement shall be subject to adjustment as provided in this Agreement for reverse and forward share splits,
Depositary Share-Ordinary Share ratio changes, share dividends, share combinations and other similar transactions of the Ordinary Shares
or Depositary Shares that occur after the date of this Agreement.

| -34- |

(m) . The Investor’s remedies provided in this Agreement, including, without limitation,
the Investor’s remedies provided in Section 9, shall be cumulative and in addition to all other remedies available to the Investor
under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy of the
Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall
limit the Investor’s right to pursue actual damages